MedPath

Sutezolid

Generic Name
Sutezolid
Drug Type
Small Molecule
Chemical Formula
C16H20FN3O3S
CAS Number
168828-58-8
Unique Ingredient Identifier
3A71182L8P
Background

Sutezolid has been used in trials studying the treatment of Tuberculosis.

Clinical Trials
Related News

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

First Posted Date
2024-01-05
Last Posted Date
2025-04-23
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
315
Registration Number
NCT06192160
Locations
🇧🇼

12701, Gaborone CRS, Gaborone, Botswana

🇧🇷

12201, Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Brazil

🇧🇷

12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio De Janeiro, Brazil

and more 22 locations

A Pan-TB Regimen Targeting Host and Microbe

Phase 2
Recruiting
Conditions
Tuberculosis
Interventions
Combination Product: Rifafour
First Posted Date
2023-01-17
Last Posted Date
2024-10-07
Lead Sponsor
The Aurum Institute NPC
Target Recruit Count
352
Registration Number
NCT05686356
Locations
🇲🇿

Instituto Nacional de Saúde, Maputo, Mozambique

🇿🇦

Clinical HIV Research Unit, Durban, South Africa

🇿🇦

The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa

and more 4 locations

PanACEA Sutezolid Dose-finding and Combination Evaluation

Phase 2
Completed
Conditions
Other Specified Pulmonary Tuberculosis
Pulmonary Tuberculosis
Interventions
Drug: Bedaquiline, Delamanid, Moxifloxacin
First Posted Date
2019-05-22
Last Posted Date
2023-05-01
Lead Sponsor
Michael Hoelscher
Target Recruit Count
75
Registration Number
NCT03959566
Locations
🇹🇿

Kilimanjaro Clinical Research Institute, Moshi, Arusha, Tanzania

🇹🇿

Ifakara Health Institute, Bagamoyo, Tanzania

🇹🇿

National Institute for Medical Research (NIMR - MMRC), Mbeya, Tanzania

and more 1 locations

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

Phase 1
Completed
Conditions
Tuberculosis
Tuberculosis, Pulmonary
Interventions
Drug: Placebo
First Posted Date
2017-06-26
Last Posted Date
2018-02-08
Lead Sponsor
Global Alliance for TB Drug Development
Target Recruit Count
32
Registration Number
NCT03199313
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

Phase 2
Completed
Conditions
Tuberculosis
Interventions
Drug: RHZE
First Posted Date
2010-10-21
Last Posted Date
2016-01-14
Lead Sponsor
Sequella, Inc.
Target Recruit Count
59
Registration Number
NCT01225640
Locations
🇿🇦

Pfizer Investigational Site, Cape Town, South Africa

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

Phase 1
Completed
Conditions
Tuberculosis
Interventions
Drug: Placebo
First Posted Date
2009-10-07
Last Posted Date
2013-08-28
Lead Sponsor
Sequella, Inc.
Target Recruit Count
59
Registration Number
NCT00990990
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

Phase 1
Completed
Conditions
Tuberculosis
Interventions
Drug: Placebo
First Posted Date
2009-03-30
Last Posted Date
2013-08-27
Lead Sponsor
Sequella, Inc.
Target Recruit Count
19
Registration Number
NCT00871949
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy